InspireMD Reports Q3 2026 Financial Results Amid U.S. Market Reentry Strategy
InspireMD (NSPR) reported third-quarter 2026 revenue of $2.2 million, an 11.1% decrease year-over-year. The decline was primarily driven by the absence of U.S. sales following a voluntary product recall in May 2026. However, international revenue grew 9.1% to $2.2 million, reflecting steady global adoption of the CGuard platform. The company reported a net loss of $9.8 million ($0.12 per share), an improvement from the $12.7 million loss in the prior-year period. To align with new commercialization priorities following FDA approval of CGuard Prime, the company implemented a 20% workforce reduction, contributing to a 26.7% decrease in operating expenses. Management is focusing on U.S. market reentry for the first half of 2027 and plans to submit a PMA supplement in December 2026. The company currently holds $19.2 million in cash and marketable securities.
Tickers: $NSPR
Topics: International growth Net loss Product recall Revenue decline Workforce reduction